Progenics Pharmaceuticals Inc
PGNX
PGNX was delisted on the 19th of June, 2020.
148 hedge funds and large institutions have $317M invested in Progenics Pharmaceuticals Inc in 2019 Q1 according to their latest regulatory filings, with 18 funds opening new positions, 62 increasing their positions, 36 reducing their positions, and 19 closing their positions.
72% more repeat investments, than reductions
Existing positions increased: 62 | Existing positions reduced: 36
2% more capital invested
Capital invested by funds: $311M → $317M (+$6.6M)
5% less first-time investments, than exits
New positions opened: 18 | Existing positions closed: 19
1% less funds holding
Funds holding: 150 → 148 (-2)
32% less call options, than puts
Call options by funds: $612K | Put options by funds: $896K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$6.97M |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$5.2M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$4.64M |
| 4 |
AAP
Ardsley Advisory Partners
Stamford,
Connecticut
|
+$3.29M |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$2.84M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$23.9M |
| 2 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$14.5M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$5M |
| 4 |
PFC
Phocas Financial Corp
Alameda,
California
|
-$2.5M |
| 5 |
Citigroup
New York
|
-$2.25M |
PGNX Hedge Fund Activity: Q1 2019 in Review
148 of the 4,621 institutional investors tracked by Wall St. Rank reported a position in Progenics Pharmaceuticals Inc (PGNX) for Q1 2019, worth a combined $317M — up 2.1% from $311M a quarter earlier.
Sellers outnumbered buyers: 19 funds closed out of PGNX and 18 opened new positions — a net loss of 1 holder — while 36 trimmed existing stakes and 62 added.
The largest buyer was Vanguard Group, adding an estimated $6.97M. The largest seller was Armistice Capital, exiting entirely with an estimated $23.9M sold.
- 148 institutional investors held Progenics Pharmaceuticals Inc (PGNX) as of Q1 2019, down from 150 in Q4 2018.
- Funds reported $317M of Progenics Pharmaceuticals Inc stock for Q1 2019, up 2.1% quarter-over-quarter.
- 18 funds opened new Progenics Pharmaceuticals Inc positions in Q1 2019 and 19 closed out, a net change of -1 holder.
- The largest Progenics Pharmaceuticals Inc buyer in Q1 2019 was Vanguard Group, an estimated $6.97M added.
- The largest Progenics Pharmaceuticals Inc seller in Q1 2019 was Armistice Capital, an estimated $23.9M sold.
Based on aggregated 13F filings for Q1 2019.